Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time
Phase III data for Medivation's MDV3100 suggest the prostate cancer drug stands to unseat J&J’s market leader Zytiga in many of the disease settings.
Phase III data for Medivation's MDV3100 suggest the prostate cancer drug stands to unseat J&J’s market leader Zytiga in many of the disease settings.